Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen: Research Supports Development of Investigational Higher Dose of Spinraza in Spinal Muscular Atrophy

06/10/2021 | 06:36am EDT

By Michael Dabaie

Biogen Inc. said new research supports continued development of an investigational higher dose of Spinraza in spinal muscular atrophy.

Analysis of data from Phase 2 and Phase 3 studies in children with infantile-onset SMA suggests that a higher dose of Spinraza may lead to a clinically meaningful increase in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders score beyond what was already observed with the 12 mg approved dose.

The data are being presented at the virtual Cure SMA Research & Clinical Care Meeting taking place June 9 to 11.

These findings reinforce the scientific rationale for evaluating a higher dose of Spinraza in the ongoing Devote Phase 2/3 study, Biogen said.

The company said it is presenting data reinforcing the long-term efficacy of Spinraza in a broad range of people with SMA

An analysis of data from a study shows 92% of patients who initiated Spinraza treatment as pre-symptomatic infants maintained the ability to swallow after a median of 3.8 years. In this analysis, study participants were consistently rated by their caregiver as, on average, never to rarely experiencing difficulty for the majority of measures related to general feeding, drinking liquids and eating solid foods, Biogen said.

In addition, post-hoc data from extension studies indicate children and teens with later-onset SMA showed improvement in walking distance over five years of Spinraza treatment and stabilization in fatigue, the company said.

Biogen licensed the global rights to develop, manufacture and commercialize Spinraza from Ionis Pharmaceuticals Inc.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

06-10-21 0836ET

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -0.67% 371.9 Delayed Quote.52.90%
DJ INDUSTRIAL -0.21% 33874.24 Delayed Quote.10.91%
IONIS PHARMACEUTICALS, INC. 0.24% 37.78 Delayed Quote.-33.34%
All news about BIOGEN INC.
05:00pEISAIá : drug for Alzheimer's with Biogen gets breakthrough status in U.S.
RE
04:28pBIOGENá : Eisai Get FDA's Breakthrough Therapy Designation for Alzheimer's Disea..
MT
04:07pBIOGENá : Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy De..
PR
04:06pBIOGENá : drug for Alzheimer's with Eisai gets breakthrough status in U.S
RE
03:27pBIOGENá : Expects 'Gradual' Uptake for Alzheimer's Drug Aduhelm, May Review Pric..
MT
12:33pBIOGENá : working to speed up confirmatory study for approved Alzheimer's drug
RE
10:16aBIOGENá : to Participate in SVB Leerink's 3rd Annual CNS Forum
AQ
07:33aBIOGENá : and Eisai Update for the Alzheimer's Disease Community
PU
06:08aNORTH AMERICAN MORNING BRIEFINGá : Stock Futures Edge Up After Nasdaq Hits Recor..
DJ
06/22NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (USD)
Sales 2021 10 635 M - -
Net income 2021 2 212 M - -
Net Debt 2021 1 495 M - -
P/E ratio 2021 26,1x
Yield 2021 -
Capitalization 56 368 M 56 368 M -
EV / Sales 2021 5,44x
EV / Sales 2022 4,99x
Nbr of Employees 9 100
Free-Float 85,8%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Last Close Price 374,40 $
Average target price 419,93 $
Spread / Average Target 12,2%
EPS Revisions
Managers and Directors
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.52.90%56 368
CSL LIMITED3.91%102 930
WUXI BIOLOGICS (CAYMAN) INC.35.21%73 428
SAMSUNG BIOLOGICS CO.,LTD.3.75%49 210
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.20.00%42 287
ALEXION PHARMACEUTICALS, INC.15.63%39 702